Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas

Hepato-Gastroenterology

Volumn 55, Issue 85, 2008, Pages 1242-1245

  Suzuki, Hideki ^a   Kuwano, Hiroyuki ^a   Masuda, Norihiro ^a   Hashimoto, Shinji ^a   Kanoh, Kenichi ^a   Nomoto, Kenichi ^a   Shimura, Tatsuo ^a   Katoh, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Endocrine tumor; FDG PET; Somatostatinoma

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SOMATOSTATINOMA;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SOMATOSTATINOMA; YOUNG ADULT;

EID: 58149394940     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Stacpoole PW, Kasselberg AG, Berelowitz M, Chey WY: Somatostatinoma syndrome: does a clinical entity exist? Acta Endocrinol (Copenh) 1983; 102(1):80-87. (Pubitemid 13169477)
2. Larsson LI, Hirsch MA, Holst JJ, et al.: Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet 1977; 1:666-668. (Pubitemid 8121565)
3. Harris GJ, Tio F, Cruz AB Jr: Somatostatinoma: a case report and review of the literature. J Surg Oncol 1987; 36(1):8-16. (Pubitemid 17139537)
4. Delcore R, Frriesen SR: Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994; 178(2):187-211. (Review) (Pubitemid 24073503)
5. Pipeleers D, Couturier E, Gepts W, Reynders J, Somers G: Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia. J Clin Endocrinol Metab 1983; 56(6):1236-1242. (Pubitemid 13055118)
6. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN: FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998; 39(6): 1030-1033. (Pubitemid 28270121)
7. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, Shumpelick V, Mittermayer C, Bull U: F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192(1):79-86. (Pubitemid 24191522)
8. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 36(5):771-777.
9. Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, Ohshio G, Imamura M, Konishi J: Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 1995; 36(2):229-235.
10. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN: 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195(2):339-344.
11. Klever P, Bares R, Fass J, Bull U, Schumpelick V: PET with fluorine-18 deoxyglucose for pancreatic disease. Lancet 1992; 340(8828):1158-1159.
12. Inoue T, Oriuchi N, Kuino M, Tomiyoshi K, Tomaru Y, Aoyagi K, Amano S, Suzuki H, Aoki J, Sato T, Endo K: Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999; 20(9):849-857. (Pubitemid 29508709)
13. Soga J, Yakuwa Y: Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrine mass. J Exp Clin Cancer Res 1999; 18(1):13-22. (Pubitemid 29232065)
14. Ganda OP, Weir GC, Soeldner JS, Legg MA, Chick WL, Patel YC, Ebeid AM, Gabbay KH, Reichlin S: "Somatostatinoma": a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 1977; 296(17):963-967. (Pubitemid 8092492)
15. Kreijs Gj, Orei L, Conlon JM, Ravazzola M, Davis GR, Raskin P, Collins SM, McCarthy DM, Baetens D, Rubenstein A, Aldor TA, Unger RH: Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med 1979; 301(6):285-292. (Pubitemid 9244490)
16. Klever P, Bares R, Fass J, Bull U, Schumpelick V: PET with fluorine-18 deoxyglucose for pancreatic disease. Lancet 1992; 340(8828):1158-1159.
17. Higashi T, Tamaki N, Honda T, Torizuka T, Kumura T, Konkuma T, Ohshio G, Hosotani R, Imamura M, Konishi J: Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997; 38(9):1337-1344. (Pubitemid 27386185)
18. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kumura T, Honda T, Inokuma T, Katsushima S, Ohshio G, Imamura M, Konishi J: FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39(10):1727-1735. (Pubitemid 28473521)
19. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E: Prognostic criteria in non-functioning pancreatic endocrine tumours. Virchows Arch 1996; 429(6):323-333. (Pubitemid 26421392)
20. Chang HJ, Batts KP, Lloyd RV, Sebo TJ, Thompson GB, Lohse CM, Pankratz SV: Prognostic significance of p27, Ki-67, and topoisomerase lla expression in clinically nonfunctioning pancreatic endocrine tumors. Endocr Pathol 2000; 11(3):229-241.
21. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A, Arimizu N: Positron emission tomography using fluorine-18- fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33(3):325-329.
22. Buck AC, Schirmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfekdt T, Reske SN: Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001; 42(5):721-725. (Pubitemid 32453459)
23. Sato T, Konishi K, Kimura H, Maeda K, Yabushita K, Tsuji M, Demachi H, Miwa A: Strategy for pancreatic endocrine tumors. Hepatogastroenterology 2000; 47(32):537-539. (Pubitemid 30216333)